RxDoctor Payments Data

Jared Yarnell, MD

Neurology · Denver, CONPI 1609215797

Payments from drug & device makers

$27,135in general payments, 2019–2025

Across 1,195 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$2K
  • Pfizer$2K
  • AstraZeneca$1K
  • Novartis$1K
  • Lilly USA, LLC$891
  • plus $16K from 54 others

What the payments were for

  • Travel & lodging$4882%
  • Food & beverage$26,62998%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)191$3,860
UCB, Inc.86$2,207
Pfizer88$1,740
AstraZeneca(2 entities)46$1,384
Novartis66$1,129
Lilly USA, LLC45$891
Teva Pharmaceuticals USA, Inc.34$882
Abbott13$863
Mallinckrodt Hospital Products Inc.48$844
Medtronic(2 entities)8$749
EMD Serono, Inc.33$708
Eisai Inc.29$610
SK Life Science, Inc.22$599
Biogen24$544
Merz Pharmaceuticals, LLC31$544
Neurocrine Biosciences, Inc.22$515
Amgen27$510
Amneal Pharmaceuticals LLC23$461
MDD US Operations, LLC26$457
Argenx US, Inc.17$423
Harmony Biosciences LLC14$412
Sanofi16$400
Genentech USA, Inc.11$394
Lundbeck LLC20$394
Neurelis, Inc.14$391
Acadia Pharmaceuticals Inc16$376
TG Therapeutics, Inc.12$367
Jazz Pharmaceuticals Inc.13$354
Biohaven Pharmaceuticals, Inc.12$307
Mallinckrodt Enterprises LLC28$300
Catalyst Pharmaceuticals, Inc.11$300
Supernus Pharmaceuticals, Inc.18$247
Bristol Myers Squibb9$219
ANI Pharmaceuticals, Inc.7$176
Otsuka America Pharmaceutical, Inc.9$173
Tanabe Pharma America, Inc.8$153
Axsome Therapeutics, Inc.5$148
Kyowa Kirin, Inc.6$142
Biohaven Pharmaceutical Holding Company Ltd.6$141
Alnylam Pharmaceuticals Inc.5$136
Merz North America, Inc.5$135
Vanda Pharmaceuticals Inc.4$134
Sunovion Pharmaceuticals Inc.7$133
Johnson & Johnson(2 entities)5$120
Boston Scientific5$115
Livanova USA, Inc.5$96
Takeda Pharmaceuticals U.S.A., Inc.3$93
Springworks Therapeutics, Inc.3$89
Grifols USA, LLC4$77
Impel Pharmaceuticals Inc.3$67
Bausch Health US, LLC3$59
Amylyx Pharmaceuticals, Inc.2$45
E.r. Squibb & Sons, L.L.C.3$43
Insightec,inc2$42
Avion Pharmaceuticals2$37
Avanir Pharmaceuticals, Inc.2$36
Banner Life Sciences, LLC2$35
Almatica Pharma LLC1$31
Nevro Corp.1$27
Nobelpharma America, LLC2$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,135 in reported general payments places this provider in the 75th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$139,426
Medicare patients
266
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$413,674
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5022$342,655
RytaryCarbidopa/Levodopa15$24,389
Nurtec OdtRimegepant Sulfate14$17,644
Ajovy AutoinjectorFremanezumab-Vfrm12$8,374
Levetiracetam85$5,324
Lacosamide17$2,844
Carbidopa-LevodopaCarbidopa/Levodopa50$2,679
Gabapentin55$2,458
Nortriptyline Hcl30$1,246
Baclofen21$1,244
Pregabalin38$1,238
Donepezil Hcl51$710
AmantadineAmantadine Hcl16$702
Lamotrigine36$564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$93$342,65522 claims
Amneal Pharmaceuticals LLCRytary$461$24,38915 claims
PfizerNurtec Odt$1,740$17,64414 claims
Almatica Pharma LLCSertraline Hcl$31$30318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 334 neurology providers in Colorado.

Other neurology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →